Rezolute, Inc. (RZLT) — SEC Filings
Rezolute, Inc. (RZLT) — 50 SEC filings. Latest: 8-K (Mar 24, 2026). Includes 30 8-K, 7 SC 13G/A, 6 10-Q.
View Rezolute, Inc. on SEC EDGAR
Overview
Rezolute, Inc. (RZLT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: Rezolute, Inc. filed an 8-K on March 24, 2026, under Regulation FD Disclosure, indicating they are sharing new, material non-public information. This filing includes an exhibit, EX-99.1, which likely contains the details of this disclosure. For investors, this matters because new information, especi
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Rezolute, Inc. is neutral.
Filing Type Overview
Rezolute, Inc. (RZLT) has filed 30 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 8-K/A, 7 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RZLT's 41 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$18.15M |
| EPS | -$0.18 |
| Debt-to-Equity | 0.08 |
| Cash Position | $9.10M |
| Operating Margin | N/A |
| Total Assets | $158.66M |
| Total Debt | $11.50M |
Key Executives
- Nevan Charles Elam
- Erik Harris
- Gil Labrucherie
- Nerissa Kreher
- Philippe Fauchet
- Wladimir Hogenhuis
- Young-Jin Kim
- Dr. Jonathan Lim
- Dr. Robert L. T. Smith
Industry Context
Rezolute operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space typically incur substantial R&D expenses for drug development and face lengthy regulatory approval processes. Success is often dependent on clinical trial outcomes and securing significant funding to advance pipeline candidates.
Top Tags
8-K (12) · disclosure (8) · financial-reporting (7) · financials (6) · 10-Q (5) · financial-statements (4) · material-agreement (4) · regulation-fd (3) · corporate-action (3) · exhibits (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $18.15M | Increased from $15.38M in Q1 2024, indicating widening losses. |
| Cash and Cash Equivalents | $9.10M | Significant decrease from $94.11M on June 30, 2025, highlighting liquidity reduction. |
| Marketable Debt Securities | $143.10M | Increased from $73.75M, showing a shift in asset allocation. |
| Net Cash Used in Operating Activities | $17.43M | High burn rate for a clinical-stage company in three months. |
| Accumulated Deficit | $422.01M | Growing deficit reflects sustained losses since inception. |
| XOMA Milestone Payment | $25.0M | Future contractual obligation upon ersodetug regulatory approval. |
| Common Shares Outstanding | 92,727,532 | As of November 4, 2025, indicating potential for further dilution. |
| Research and Development Expenses | $13.15M | Slight increase from $12.75M in Q1 2024, reflecting ongoing clinical trials. |
| General and Administrative Expenses | $6.67M | Increased from $4.19M in Q1 2024, contributing to higher operating costs. |
| Interest and Other Income, net | $1.68M | Increased from $1.58M in Q1 2024, providing some offset to losses. |
| Filing Date | 2025-10-07T00:00:00.000Z | Date the DEF 14A was filed |
| Annual Meeting Date | 2025-11-19T00:00:00.000Z | Date of the 2026 Annual Meeting of Stockholders |
| Annual Meeting Time | 3:00 p.m. Pacific Time | Scheduled time for the virtual Annual Meeting |
| Record Date | 2025-09-22T00:00:00.000Z | Date for stockholders of record entitled to vote |
| Shares Outstanding | 90,828,052 | Number of common stock shares entitled to vote as of the Record Date |
Frequently Asked Questions
What are the latest SEC filings for Rezolute, Inc. (RZLT)?
Rezolute, Inc. has 50 recent SEC filings from Feb 2024 to Mar 2026, including 30 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RZLT filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Rezolute, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rezolute, Inc. (RZLT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rezolute, Inc.?
Key financial highlights from Rezolute, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RZLT?
The investment thesis for RZLT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rezolute, Inc.?
Key executives identified across Rezolute, Inc.'s filings include Nevan Charles Elam, Erik Harris, Gil Labrucherie, Nerissa Kreher, Philippe Fauchet and 4 others.
What are the main risk factors for Rezolute, Inc. stock?
Of RZLT's 41 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Rezolute, Inc.?
Forward guidance and predictions for Rezolute, Inc. are extracted from SEC filings as they are enriched.